Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19410533 | 0.94 | ACLY (0.43) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL19410452 | 0.92 | ACLY (0.42) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL19410501 | 0.82 | ACLY (0.42) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL184044 | 0.80 | BCL2 (0.53) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL19410532 | 0.78 | ACLY (0.44) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL10246826 | 0.75 | ACLY (0.55) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL19410451 | 0.74 | ACLY (0.41) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL185470 | 0.72 | BCL2 (0.53) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL185342 | 0.71 | BCL2 (0.58) | ACLYBCL2MMP1MMP2MMP9 | |
| SCHEMBL185430 | 0.69 | BCL2 (0.66) | ACLYBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | ACLY 1867/4885BCL2 520/4885MMP1 1804/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | ACLY 2754/4885BCL2 132/4885MMP1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.